Batch to batch reproducibility and homogeneity create a stable human model for the study of muscle, neuromuscular, and associated metabolic disorders.
Form striated, multinucleated, myocytes by Day 10 post revival, that contract in response to acetylcholine.
Industrial scale quantities at a price point that allows the cells to be used from research to screening scale.
Cells arrive programmed to rapidly mature upon revival. One medium required in a two-step protocol.
A. Desmin (red) / DAPI (blue)
B. Dystrophin (green) / DAPI (blue)
C. Myogenin (green) / MHC (red)
D. Troponin (green) / Phalloidin (red) / DAPI (blue)
“One of the biggest advantages of the ioSkeletal Myocytes is within the early drug discovery phase. You can very quickly screen a large number of molecules in a short amount of time with minimal variability and high reproducibility.”
Dr Shushant Jain
Group Leader | In Vitro Biology | Charles River
"The ioSkeletal Myocytes have a much shorter cell culture time compared to harvesting primary muscle cells, saving us months on cell culture work. Another advantage of these cells is their higher population purity compared to other stem cell derived cells. This enables us to achieve higher numbers of functional striated muscle that are capable of contracting under electrical stimulation. This considerably increases the pace at which we can test our bioelectronics devices."
Amy Rochford
PhD Neural Engineering and Bioelectronics | Cambridge University
“We can now start asking questions that, ten years ago, we didn’t know how to answer,” Duchen reflects. “If you have a really good disease model, then the only limit is your imagination.”
Dr Michael Duchen
Professor of Physiology | University College London
